Sequella, Inc.
Sequella is a privately held, clinical-stage biopharmaceutical company focused on discovery, development, and commercialization of novel small-molecule antibiotics targeting drug-resistant bacterial, fungal, and parasitic infections. The company operates discovery chemistry and microbiology laboratories (including BSL-3 capability), manages a large proprietary small-molecule library, advances multiple clinical- and preclinical-stage antibiotic candidates, and pursues partnerships and out-licensing for regional development and diagnostics commercialization.
Industries
Nr. of Employees
small (1-50)
Sequella, Inc.
9610 Medical Center Drive, Ste 200, Rockville, MD 20850, USA
Patents
Products
SQ109 (small-molecule diamine antibiotic)
Orally bioavailable small-molecule antibiotic discovered via combinatorial screening with activity against drug-susceptible and drug-resistant Mycobacterium tuberculosis and activity in other pathogens; demonstrated safety in Phase 1 studies and advanced through Phase 2 trials.
Sutezolid (oxazolidinone antibiotic)
Oxazolidinone-class antibiotic in Phase 2 development (licensed from a major pharmaceutical company) with demonstrated antimycobacterial activity and early bactericidal activity in humans.
SQ641 (capuramycin-derived Translocase-1 inhibitor)
Semi-synthetic capuramycin-derived compound targeting bacterial translocase-1, developed for treatment of Clostridium difficile infection with high local GI exposure and demonstrated efficacy in murine models.
SQ609 (dipiperidine small-molecule antibiotic)
Preclinical antitubercular candidate from a dipiperidine series with activity against M. tuberculosis, favorable ADME/toxicology attributes, and a defined scalable synthesis.
B-SMART technology (nucleic-acid based phenotypic susceptibility platform)
A nucleic acid–based reporter approach that measures microbial viability and antimicrobial susceptibility by combining molecular detection with phage-based viability readouts to deliver rapid susceptibility results.
SQ109 (small-molecule diamine antibiotic)
Orally bioavailable small-molecule antibiotic discovered via combinatorial screening with activity against drug-susceptible and drug-resistant Mycobacterium tuberculosis and activity in other pathogens; demonstrated safety in Phase 1 studies and advanced through Phase 2 trials.
Sutezolid (oxazolidinone antibiotic)
Oxazolidinone-class antibiotic in Phase 2 development (licensed from a major pharmaceutical company) with demonstrated antimycobacterial activity and early bactericidal activity in humans.
SQ641 (capuramycin-derived Translocase-1 inhibitor)
Semi-synthetic capuramycin-derived compound targeting bacterial translocase-1, developed for treatment of Clostridium difficile infection with high local GI exposure and demonstrated efficacy in murine models.
SQ609 (dipiperidine small-molecule antibiotic)
Preclinical antitubercular candidate from a dipiperidine series with activity against M. tuberculosis, favorable ADME/toxicology attributes, and a defined scalable synthesis.
B-SMART technology (nucleic-acid based phenotypic susceptibility platform)
A nucleic acid–based reporter approach that measures microbial viability and antimicrobial susceptibility by combining molecular detection with phage-based viability readouts to deliver rapid susceptibility results.
Services
Licensing of development and commercialization rights, structuring partnerships that include equity, milestone, and royalty arrangements for regional markets.
Collaboration and coordination with academic consortia and funding bodies to run multi-site international clinical trials, including MAMS trial designs.
Licensing of development and commercialization rights, structuring partnerships that include equity, milestone, and royalty arrangements for regional markets.
Collaboration and coordination with academic consortia and funding bodies to run multi-site international clinical trials, including MAMS trial designs.
Expertise Areas
- Antibacterial small-molecule discovery
- Combatorial chemistry and medicinal chemistry
- Preclinical pharmacology and animal efficacy models
- Clinical trial design and international execution
Key Technologies
- Combinatorial chemistry and focused library synthesis
- High-throughput whole-cell screening
- BSL-3 laboratory operations
- In vivo murine and larger animal efficacy models
News & Updates
Press release reporting positive results from a randomized, double-blind, placebo-controlled Phase 2b-3 study of SQ109 added to standard MDR-TB therapy in Russia, showing improved sputum culture conversion and tolerability.
Announcement of enrollment of first patient into a Phase 2 MAMS clinical trial in Tanzania and South Africa to evaluate regimens including SQ109 to shorten TB treatment duration.
Press release describing a licensing agreement to enable development of a nucleic-acid-based rapid susceptibility assay for Mycobacterium tuberculosis using a viability-reporting approach.
Press release announcing licensing of worldwide development and commercialization rights to an oxazolidinone antibiotic in clinical development for TB.
Announcement of a licensing and partnership agreement to complete clinical development and commercialization of SQ109 in Russia and Commonwealth of Independent States.
Press release describing multiple NIH/NIAID grants to support development of ethylenediamine-based antibiotics for C. difficile and to support clinical infrastructure for TB trials.
Press release reporting positive results from a randomized, double-blind, placebo-controlled Phase 2b-3 study of SQ109 added to standard MDR-TB therapy in Russia, showing improved sputum culture conversion and tolerability.
Announcement of enrollment of first patient into a Phase 2 MAMS clinical trial in Tanzania and South Africa to evaluate regimens including SQ109 to shorten TB treatment duration.
Press release describing a licensing agreement to enable development of a nucleic-acid-based rapid susceptibility assay for Mycobacterium tuberculosis using a viability-reporting approach.
Press release announcing licensing of worldwide development and commercialization rights to an oxazolidinone antibiotic in clinical development for TB.
Announcement of a licensing and partnership agreement to complete clinical development and commercialization of SQ109 in Russia and Commonwealth of Independent States.
Press release describing multiple NIH/NIAID grants to support development of ethylenediamine-based antibiotics for C. difficile and to support clinical infrastructure for TB trials.